A comprehensive medical evaluation, including a review of health history, current medications, and overall wellness, is crucial
Thats why every program is built around your unique biology, lifestyle, and goals
In the STEP 1 clinical trial (NEJM, 2021), participants on semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks (about 33.6 lbs from a 232 lb average baseline) vs 2.4% with placebo
This indicates protein aggregation or bacterial contamination
Why Choose Foundations at Maitland
Consistent with these findings, the current study confirmed that the semaglutide-intensified treatment group exhibited reduced fasting plasma glucose, fasting insulin, total cholesterol, triglyceride, and LDL-C levels compared with baseline